

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 563 714 A2**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: **93104591.8**

(51) Int. Cl.<sup>5</sup>: **C12N 15/28, C12P 21/02,  
C07K 13/00, C12N 1/21,  
A61K 37/02**

(22) Date of filing: **20.03.93**

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(30) Priority: **02.04.92 EP 92810249**

(43) Date of publication of application:  
**06.10.93 Bulletin 93/40**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC  
NL PT SE**

(71) Applicant: **F. HOFFMANN-LA ROCHE AG  
Postfach 3255  
CH-4002 Basel(CH)**

(72) Inventor: **Lesslauer, Werner  
288 Aeussere Baselstrasse  
CH-4125 Riehen(CH)  
Inventor: Lötscher, Hansruedi  
18 Frankenstrasse  
CH-4313 Möhlin(CH)  
Inventor: Stüber, Dietrich  
9 Bandweg  
W-7889 Grenzach-Wyhlen(DE)**

(74) Representative: **Mezger, Wolfgang, Dr. et al  
Grenzacherstrasse 124  
Postfach 3255  
CH-4002 Basel (CH)**

(54) **TNF-Muteln.**

(57) The present invention is directed to a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof having selective binding affinity for the human p55-Tumor-Necrosis-Factor-Receptor characterized in that the amino acid sequence of human Tumor Necrosis Factor is changed at least at position 86 showing a threonine instead of a serine residue, a DNA sequence coding for such a mutein, a vector comprising such a DNA sequence, a host cell transformed by such a vector, a process for the production of such muteins by such host cells, pharmaceutical compositions containing such a mutein and the use of such a mutein for the treatment of illnesses.

**EP 0 563 714 A2**

33

26

Tumor Necrosis Factor, or more specifically Tumor Necrosis Factor-alpha (TNF- $\alpha$ ), is a cytokine, primarily produced by stimulated macrophages, that exhibits not only a striking cytotoxicity against various tumour cells [Carswell et al., *Proc. Nat. Acad. Sci., U.S.A.* 72, 3666-3670, (1975)] but also plays a multiple role as a mediator of inflammation and the immune response [for an overview see Beutler and Cerami, *Ann. Rev. Immunol.* 7, 625-655 (1989); Bonavista and Granger (eds.) "Tumor Necrosis Factor: Structure, Mechanism of Action, Role in Disease and Therapy, Karger, Basel (1990)]. The primary structure of human Tumor Necrosis Factor-alpha (hTNF- $\alpha$ ) has been deduced from the nucleotide sequence of a cDNA which has been cloned and expressed in *E. coli* [Pennica et al., *Nature* 312, 724-729 (1984); Marmenout et al., *Europ. J. Biochem.* 152, 515-522 (1985); Wang et al., *Science* 228, 149-154 (1985); Shirai et al., *Nature* 313, 803-806 (1985)]. A striking homology in amino acid sequence (30%) was found between hTNF- $\alpha$  and human Lymphotoxin, often referred to as human Tumor Necrosis Factor-beta (hTNF- $\beta$ ), a cytokine mainly produced by lymphocytes (Gray et al., *Nature* 312, 721-724 (1984); Fiers et al., *Cold Spring Harbour Symp.* 51, 587-595 (1986)].

hTNF- $\alpha$  with modified amino acid sequences, so called TNF- $\alpha$ -muteins, have also been described in the art [for example see Yamagishi et al., *Protein Engineering* 3, 713-719, (1990) or by Fiers in "Tumor Necrosis Factors: Structure, Function and Mechanism of Action", Aggarwal and Vilcek (eds.), Marcel Dekker, Inc., New York, in press, or by Fiers et al. in Bonavista and Granger, pp. 77-81 (s.a.)]. In addition TNF- $\alpha$ -muteins have also been the object of several patent applications, e.g. International Patent Applications Publ. Nos. WO 86/02381, WO 86/04606, WO 88/06625 and European Patent Applications Publ. Nos. 155,549; 158,286; 168,214; 251,037 and 340,333, and Deutsche Offenlegungsschrift Nr. 3843534.

Muteins of Lymphotoxin have also been disclosed in the art, e.g. in European Patent Applications Publ. Nos. 250,000; 314,094 and 336,383.

The biological effects of TNF are mediated via specific receptors, namely a receptor with an apparent molecular weight of 55 kD on sodium dodecylsulfate polyacrylamid gel electrophoresis (SDS-PAGE) (p55-TNF-R) and a receptor with an apparent molecular weight of 75 kD on SDS-PAGE (p75-TNF-R). Both forms of TNF-receptors have been cloned, namely p55-TNF-R by Loetscher et al. [*Cell* 61, 351-359, (1990)] and p75-TNF-R for example by Dembic et al. [*Cytokine* 2, 53-58, (1990)] (for both receptors see also European Patent Application No. 90116707.2) and it was found more recently that both receptors bind not only TNF- $\alpha$  but also TNF- $\beta$  with high affinity [Schönfeld et al., *J. Biol. Chem.* 266, 3863-3869 (1991)].

It is well known in the art that on the basis of its biological activities TNF- $\alpha$  can be a valuable compound for the treatment of various disorders. For example TNF- $\alpha$ , alone or in combination with interferon, can be an effective antitumor agent [Brouckaert et al., *Int. J. Cancer* 38, 763-769 (1986)]. However, its systemic toxicity is a major limitation to its wider therapeutic use [Taguchi T. and Sohmura Y., *Biotherapy* 3, 177-186 (1991)].

It has been shown that in mice human TNF- $\alpha$  (hTNF- $\alpha$ ), which only binds to the smaller mouse TNF receptor (murine p55-TNF-R) is far less toxic than murine TNF- $\alpha$  (mTNF- $\alpha$ ), which binds to both p55-TNF-R and p75-TNF-R. For example, in C57B16 mice, the LD50 is about 10  $\mu$ g/mouse and 500  $\mu$ g/mouse with mTNF- $\alpha$  and hTNF- $\alpha$ , respectively [Brouckaert et al., *Agents and Actions* 26, 196-198 (1989); Everaerd, B. et al., *Biochem. Biophys. Res. Comm.* 163, 378-385 (1989); Lewis, M. et al., *Proc. Natl. Acad. Sci. USA* 88, 2830 (1991)]. Hence the p75-TNF-R seems to play a special role in systemic toxicity.

hTNF- $\alpha$  and mTNF- $\alpha$  bind almost equally to human p55-TNF-R and to human p75-TNF-R. However, hTNF- $\alpha$  mutants, which have retained the biological activity mediated by hp55-TNF-R but have lost nearly all activity on hp75-TNF-R, are the functional equivalent of hTNF- $\alpha$  in the murine system, and are expected to have reduced systemic toxicity in primates.

Human Tumor Necrosis Factor muteins, showing a significant difference between their binding affinity to the human p75-Tumor-Necrosis-Factor-Receptor (hp75-TNF-R) and to the human p55-Tumor-Necrosis-Factor-Receptor (hp55-TNF-R), have been described in European Patent Application, Publication No. 486 908.

It has now been found that hTNF muteins or pharmaceutically salts thereof, having the amino acid sequence of human Tumor Necrosis Factor, changed at least at position 86 (showing a threonine instead of a serine residue), have retained the binding activity to hp55-TNF-R, but have lost nearly all binding to hp75-TNF-R. Furthermore, such hTNF muteins have been found which have retained biological activity mediated by hp55-TNF-R, while no longer binding to hp75-TNF-R. However, the hTNF muteins of the present invention are not restricted to this type of mutein. Muteins of another type still binding exclusively to hp55-TNF-R but having lost the capacity to elicit a functional cell response are also included.

The present invention, therefore, provides human Tumor Necrosis Factor muteins or pharmaceutically acceptable salts thereof, having selective binding affinity for the human p55-Tumor-Necrosis-Factor-Receptor (hp55-TNF-R) characterized in that the amino acid sequence of human Tumor Necrosis Factor is

changed at least at position 86, showing a threonine instead of a serine residue.

The amino acid sequence of human TNF- $\alpha$  as disclosed by Pennica et al. [s.a.] is as follows:

```

5      1                               10
      VAL ARG SER SER SER ARG THR PRO SER ASP LYS PRO VAL ALA HIS

      20                               30
      VAL VAL ALA ASN PRO GLN ALA GLU GLY GLN LEU GLN TRP LEU ASN
10
      40
      ARG ARG ALA ASN ALA LEU LEU ALA ASN GLY VAL GLU LEU ARG ASP

      50                               60
15     ASN GLN LEU VAL VAL PRO SER GLU GLY LEU TYR LEU ILE TYR SER

      70
      GLN VAL LEU PHE LYS GLY GLN GLY CYS PRO SER THR HIS VAL LEU

      80                               90
20     LEU THR HIS THR ILE SER ARG ILE ALA VAL SER TYR GLN THR LYS

      100
      VAL ASN LEU LEU SER ALA ILE LYS SER PRO CYS GLN ARG GLU THR
25
      110                               120
      PRO GLU GLY ALA GLU ALA LYS PRO TRP TYR GLU PRO ILE TYR LEU

      130
30     GLY GLY VAL PHE GLN LEU GLU LYS GLY ASP ARG LEU SER ALA GLU

      140                               150
      ILE ASN ARG PRO ASP TYR LEU ASP PHE ALA GLU SER GLY GLN VAL

      157
35     TYR PHE GLY ILE ILE ALA LEU

```

or as disclosed by Marmenout et al. (s.a.) or Wang et al. (s.a.) or Shirai et al. or more specifically as coded for by the nucleotide sequence of the insert of the plasmid pDS56/RBSII, SphI-TNF $\alpha$  (see Figures 1a and 1b and Example I) coding for mature TNF- $\alpha$ .

The hTNF muteins as defined above may have changed the amino acid sequence of hTNF at one or more additional positions, preferably at one or two additional positions, whereby positions 29, 31, 32, 29 and 32, or 31 and 32 are especially preferred. Any amino acid, preferably any naturally occurring one, can be used at these additional positions. For substitutions at position 29 serine, glycine or tyrosine are preferred, whereby serine is especially preferred. For substitutions at position 31 glutamic acid or asparagine are preferred. For substitutions at position 32 tyrosine, tryptophan or threonine are preferred, whereby tryptophan and threonine are specifically preferred.

The hTNF muteins of the present invention may contain further amino acid substitutions if such substitutions do not alter their selective binding affinity for the p55-TNF-R. Amino acid substitutions in proteins and polypeptides which do not essentially alter biological activity are known in the art and described, e.g. by H. Neurath and R.L. Hill in "The Proteins", Academic Press, New York (1979), in particular in fig. 6 of page 14. The most frequently observed amino acid substitutions are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly and vice versa. The hTNF muteins of the present invention may additionally contain sequences of several amino acids which are coded for by "linker" sequences. These sequences may arise as a result from the expression vectors used for expression of the hTNF muteins as defined above.

The hTNF muteins of the present invention can also contain specific sequences that preferably bind to an affinity carrier material. Examples of such sequences are sequences containing at least two adjacent histidine residues (see in this respect European Patent Application, Publication No. 282 042). Such sequences bind selectively to nitrilotriacetic acid nickel chelate resins (Hochuli and Döbeli, *Biol. Chem. Hoppe-Seyler* 368, 748 (1987); European Patent Application, Publication No. 253 303). hTNF muteins which contain such a specific sequence can be linked either to the C-terminus or the N-terminus, or to both termini, of the hTNF-mutein amino acid sequences.

The hTNF muteins of the present invention can also be combined with different immunoglobulin heavy chain or light chain polypeptides. This leads to chimaeric hTNF mutein immunoglobulin polypeptides which could have increased half-life in vivo. Increased half-life in vivo has been shown, e.g., for chimeric polypeptides consisting of the first two domains of the constant regions of the heavy chain or the light chain of a mammalian immunoglobulin (see Traunecker et al., *Nature* 331, 84-86 [1988] and European Patent Application, Publication No. 394 827).

The hTNF muteins can also be coupled to polymers, e.g. polyethylene glycol or polypropylene glycol having a molecular weight of 500 to 20.000 daltons. This leads to protected hTNF mutein compositions which could be substantially non-immunogenic. Several modes of coupling the polymer with the polypeptide are available and described. e.g., in U.S. Patent No. 4.179.337.

Especially preferred hTNF muteins of the present invention are Thr<sup>86</sup>-TNF- $\alpha$ , Ser<sup>29</sup>-Thr<sup>86</sup>-TNF- $\alpha$ , Glu<sup>31</sup>-Thr<sup>86</sup>-TNF- $\alpha$ , Trp<sup>32</sup>-Thr<sup>86</sup>-TNF- $\alpha$ , Ser<sup>29</sup>-Trp<sup>32</sup>-Thr<sup>86</sup>-TNF- $\alpha$  or Asn<sup>31</sup>-Thr<sup>32</sup>-Thr<sup>86</sup>-TNF- $\alpha$ .

The hTNF muteins of the present invention can be produced by methods known in the art and described e.g. in Sambrook et al. [*Molecular Cloning, A Laboratory Manual*, 2nd ed., Cold Spring Harbour Laboratory, Cold Spring Harbour Laboratory Press, USA (1989)] or in the following paragraphs. Whether such hTNF muteins still show selective binding affinity for the p55-TNF-R can be determined as described in the following Examples. Alternatively, the hTNF muteins of the present invention can also be chemically synthesized using standard methods known in the art, preferably solid state methods, such as the methods of Merrifield (*J. Am. Chem. Soc.* 85, 2149-2154 [1963]). Furthermore salts of such muteins are also an object of the present invention. Such salts can be produced by methods known in the art.

It is believed that the strategy of dissecting beneficial and unwanted TNF- $\alpha$  activities by using compounds specifically binding to one or the other TNF-receptor, such as the hTNF muteins of the present invention, can be used in general in other disease states where TNF plays a role.

DNA-sequences comprising a DNA-sequence coding for hTNF-muteins as hereinbefore described are also an object of the present invention. Such DNA-sequences can be constructed starting from genomic- or cDNA-sequences coding for hTNF as disclosed in the art [s.a.] using known methods of in vitro mutagenesis [see e.g. Sambrook et al., 1989]. Such mutagenesis can be carried out ad-random in order to obtain a large number of mutants which can then be tested for their desired properties in appropriate assay systems or, in order to mutate defined positions in a given DNA-sequence, by so called site directed mutagenesis [see e.g. Sambrook et al., 1989, 15.51-15.113] or by mutagenesis using the polymerase chain reaction [see e.g. White et al., *Trends in Genetics* 5, 185-189 (1989)].

One chemical mutagen which is often used for mutagenesis ad-random is sodium bisulfite which converts a cytosine residue into an uracil residue and hence leads to a transition of "C" to "T" (standard abbreviations for nucleotides) [for the method see e.g. Shortle and Nathans, *Proc. Nat. Acad. Sci. U.S.A.* 75, 2170-2174 (1978) or Pine and Huang, *Meth. Enzym.* 154, 415-430 (1987)]. This mutagen acts solely on single stranded DNA whereas the expression of the mutated target DNA sequence is achieved with a double stranded plasmid vector. One possibility to avoid the necessity of recloning in mutagenesis and expression vectors is the use of so called "phasmids". These are vectors which, in addition to a plasmid origin of replication, carry also an origin of replication derived from a filamentous phage. Examples of such phasmids are the pMa- and pMc-phasmids as described by Stanssen et al. [*Nucleic Acids Res.* 17, 4441-4454, (1989)]. Using this expression system one can construct so called "gap-duplex"-structures [see also Kramer et al., *Nucl. Acids. Res.* 12, 9441-9456 (1984)] where only the TNF-coding sequence (s.a.) is in a single stranded configuration and therefore accessible for the specific chemical mutagen. "gap-duplexes" to be used in ad-random mutagenesis can be constructed as described for site-specific mutagenesis by Stanssen et al. [s.a.] with the exception that the (-)strand contains the same active antibiotic resistance gene as the (+)strand. By making use of different restriction sites in the DNA-sequence encoding hTNF $\alpha$ , variation of the width of the gap is possible. Examples of such restriction sites are the ClaI-SalI sites (470 nucleotides), BstXI-BstXI sites (237 nucleotides) or Styl-Styl sites (68 nucleotides). Such gap-duplex-constructs can then be treated with increasing concentrations (up to 4M) of bisulfite, followed by several dialysis steps, as described by Shortle and Nathans (s.a.). A suitable procaryotic host cell can then be transformed by such phasmid constructs according to methods known in the art and described e.g. by

Sambrook et al. (s.a.). A suitable procaryotic host cell means in this context a host cell deficient in a specific repair function so that an uracil residue is maintained in the DNA during replication and which host cell is capable of expressing the corresponding mutated TNF. Such specific host strains are known in the art, for example for *E. coli* strains, e.g. *E. coli* BW 313 [Kunkel, T.A., *Proc. Natl. Acad. Sci. USA* 82, 488-492 (1985)]. The resulting clones can then be screened for those expressing a desired hTNF mutein by appropriate assay systems. For example each colony can be inoculated in a microtiterplate in a suitable medium containing the relevant antibiotic. The cells may be lysed by addition of lysozyme, followed by sequential freeze-thaw cycles. After precipitation of nucleic acids and centrifugation, the supernatant of each colony can directly be used in appropriate assays as described, e.g., in Example IIa and IIb or Example VIII measuring binding to the p75-TNF-R and the p55-TNF-R on the surface of living cells or in purified form.

If desired, the specific sites of mutation can be determined, for example by restriction fragment analysis [see e.g. Sambrook et al. (s.a.)]. By determination of the DNA-sequence of such fragments the exact position of the mutation can be determined and if such mutation leads to an amino acid replacement the new amino acid can be derived from the determined DNA-sequence. DNA-sequencing can be performed according to methods known in the art, e.g. by using T7 polymerase on supercoiled DNA with a commercially available sequencing kit (Pharmacia, Uppsala, Sweden).

As already mentioned above, another possibility of mutating a given DNA-sequence is by "site directed mutagenesis". A widely used strategy for such kind of mutagenesis as originally outlined by Hutchinson and Edgell [*J. Virol.* 8, 181 (1971)] involves the annealing of a synthetic oligonucleotide carrying the desired nucleotide substitution to a target region of a single-stranded DNA-sequence wherein the mutation should be introduced [for review see Smith, *Annual. Rev. Genet.* 19, 423 (1985) and for improved methods see references 2-6 in Stanssen et al. (1989)].

One such preferred method is the one of Stanssen et al. (1989) using "gapped duplex DNA" as originally described by Kramer et al. (1984) [see above and Kramer and Fritz, *Methods in Enzymology*, (1987), Academic Press, Inc., USA] but using antibiotic resistance genes instead of M13 functional genes for selection of the mutation containing strand in addition with the phasmid-technology as also described by Stanssen et al. (1989) [s.a.]. An advantage of this method lies also in the capability of performing successive cycles of mutagenesis without the need to transfer the gene to a new mutagenesis vector: second round mutagenesis differs only in the selection to another antibiotic marker (Stanssen et al., s.a.). As a control site-specific back mutagenesis of the mutant to the wild-type TNF can be used. In addition, the use of an oligonucleotide, creating or destroying a restriction site in the TNF gene, allows to control the mutant not only by hybridization to the oligonucleotide used for site directed mutagenesis but also by the presence or absence of the restriction site. In order to create a set of hTNF muteins wherein at a defined position of their amino acid sequence the wild-type amino acid is replaced by any naturally occurring amino acid a set of oligonucleotides is used with all possible codons at the defined position.

As already mentioned above, another possibility of mutating a given DNA-sequence is the mutagenesis by using the polymerase chain reaction (PCR). The principles of this method are outlined e.g. by White et al. (1989), whereas improved methods are described e.g. in Innis et al. [PCR Protocols: A Guide to Methods and Applications, Academic Press, Inc. (1990)].

PCR is an in vitro method for producing large amounts of a specific DNA fragment of defined length and sequence from small amounts of a template DNA. Thereby, PCR is based on the enzymatic amplification of the DNA fragment which is flanked by two oligonucleotide primers that hybridize to opposite strands of the target sequence. The primers are oriented with their 3' ends pointing towards each other. Repeated cycles of heat denaturation of the template, annealing of the primers to their complementary sequences and extension of the annealed primers with a DNA polymerase result in the amplification of the segment between the 5' ends of the PCR primers. Since the extension product of each primer can serve as a template for the other, each cycle essentially doubles the amount of the DNA fragment produced in the previous cycle. Since the primers are physically incorporated into the amplified product and mismatches between the 5' end of the primer and the template do not significantly affect the efficiency of the amplification, it is possible to alter the amplified sequence thereby introducing the desired mutation into the amplified DNA. By utilizing the thermostable Taq DNA polymerase isolated from the thermophilic bacteria *Thermus aquaticus*, it has been possible to avoid denaturation of the polymerase which necessitated the addition of enzyme after each heat denaturation step. This development has led to the automation of PCR by a variety of simple temperature-cycling devices. In addition, the specificity of the amplification reaction is increased by allowing the use of higher temperatures for primer annealing and extension. The increased specificity improves the overall yield of amplified products by minimizing the competition by non-target fragments for enzyme and primers.

Design and synthesis of oligonucleotides can be effected as known in the art and described e.g. in Sambrook et al. (1989) or in one of the references cited above with respect to site directed mutagenesis.

As soon as a DNA-sequence coding for a hTNF-mutein of the present invention has been created, expression can be effected by the phasmid technology as described above or by use of any suitable pro-or eukaryotic expression system well known in the art [see e.g. Sambrook et al., s.a.].

Expression is effected preferably in prokaryotic cells, e.g., in *E. coli*, *Bacillus subtilis* and so on, whereby *E. coli*, specifically *E. coli* K12 strains e.g. M15 [described as DZ 291 by Villarejo et al. in *J. Bacteriol.* 120, 466-474 (1974)], HB 101 [ATCC No. 33694], WK6 (Stranssens et al. s.a.) or *E. coli* SG13009 [Gottesman et al., *J. Bacteriol.* 148, 265-273 (1981)] are preferred. Expression of the hTNF muteins of the present invention can also be effected in lower or higher eukaryotic cells, like for example yeast cells (like *Saccharomyces*, *Pichia* etc.), filamentous fungi (like *Aspergillus* etc.) or cell lines (like chinese hamster ovary cell lines etc.), whereby expression in yeast cells is preferred [see Sreekrishna et al., *Biochem.* 28, 4117-4125, (1989); Hitzeman et al., *Nature* 293, 717-722 (1981); European Patent Application Publication No. 263 311]. Expression of the hTNF muteins of the present invention may occur in such systems either intracellularly, or, after suitable adaption of the gene, extracellularly (see Lœmans et al., *Gene* 85, 99-108, 1989).

Suitable vectors used for expression in *E. coli* are mentioned e.g. by Sambrook et al. [s.a.] or by Fiers et al. in "Proc'd. 8th Int. Biotechnology Symposium" [Soc. Franc. de Microbiol., Paris, (Durand et al., eds.), pp. 680-697 (1988)] or and more specifically vectors of the pDS family [Bujard et al., *Methods in Enzymology*, eds. Wu and Grossmann, Academic Press, Inc. Vol. 155, 416-433 (1987); Stüber et al., *Immunological Methods*, eds. Lefkovits and Pernis, Academic Press, Inc., Vol. IV, 121-152 (1990)] like for example pDS56/RBSII, SphI-TNF $\alpha$ (Thr86) (see Example I) or pDS56/RBSII, SphI-TNF $\alpha$ (Trp32Thr86) (see Example III) or pDS56/RBSII, SphI-TNF $\alpha$ (Ser29Thr86) or pDS56/RBSII, SphI-TNF $\alpha$ (Ser29Trp32Thr86) or pDS56/RBSII, SphI-TNF $\alpha$ (Asn31Thr32Thr86) or pDS56/RBSII, SphI-TNF $\alpha$ (Glu31Thr86) (see Example IV). Since with these specific pDS56/RBSII-plasmids due to their specific regulatable promoter/operator elements and ribosomal binding sites a high level of expression can be achieved, the plasmids can be maintained in *E. coli* cells only when the activity of the promoter/operator element is repressed by the binding of a lac repressor to the operator. The activity of the promoter can be restored at the desired cell density by addition of IPTG, which inactivates the repressor and clears the promoter. Since most of the *E. coli* strains do not provide enough repressor molecules to completely repress the function of the promoter sequences present in these high copy number plasmids, such *E. coli* strains, like *E. coli* M15 or SG13009, have to be transformed at first with a plasmid, like pREP 4 (see Figures 2a and b), coding for the lac repressor, before being transformed with the specific pDS56/RBSII-plasmids of the invention which can then be stably maintained in the *E. coli* cells. Beside coding for the lac repressor, pREP4 contains also a region of the plasmid pACYC184 [Chang and Cohen, *J. Bacteriol.* 134, 1141-1156 (1978)], which contains all information required for replication and stable transmission to daughter cells [for additional information see also "System for high level production in *E. coli* and rapid purification of recombinant proteins: application to epitope mapping, preparation of antibodies and structure function analysis" by Stüber et al. in *Immunological Methods*, Vol. IV, pp 121-152, Lefkovits and Pernis (eds.), Academic Press, New York (1990)].

Transformation of the host cells by vectors as described above may be carried out by any conventional procedure [see for example Sambrook et al. (s.a.)]. Where the host cell is a prokaryote, such as *E. coli* for example, competent cells which are capable of DNA uptake are prepared from cells harvested after exponential growth phase and subsequently treated according to the known CaCl<sub>2</sub>-method. Transformation can also be performed after forming a protoplast of the host cell or by other methods known in the art and described, e.g., in Sambrook et al. (s.a.). Therefore a vector, especially for expression in a prokaryotic or lower eukaryotic host cell, comprising a DNA-sequence coding for an hTNF mutein as described above, and a host cell, especially a prokaryotic host cell, e.g. *E. coli*, or a lower eukaryotic host cell, transformed by such a vector are also an object of the present invention.

Usually, the host organisms which contain a desired expression vector are grown under conditions which are optimal for their growth. In case of a prokaryotic host at the end of the exponential growth, when the increase in cell number per unit time decreases, the expression of the desired hTNF mutein is induced, i.e. the DNA coding for the desired hTNF mutein is transcribed and the transcribed mRNA is translated. The induction can be carried out by adding an inducer or a derepressor to the growth medium or by altering a physical parameter, e.g. a change in temperature. In the expression vectors used in the preferred embodiments of the present invention, the expression is controlled by the lac repressor. By adding isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG), the expression control sequence is derepressed and the synthesis of the desired hTNF mutein is thereby induced.

The hTNF muteins of the present invention produced by transformed host cells as stated above can be recovered from the culture medium or after opening the cells and/or extraction by any appropriate method known in protein and peptide chemistry such as, for example, precipitation with ammonium sulfate, dialysis, ultrafiltration, gel filtration or ion-exchange chromatography, gel electrophoresis, isoelectric focusing, affinity chromatography, like immunoaffinity chromatography, HPLC or the like. Specifically preferred methods are precipitation with ammonium sulfate and/or polyethylenimine, dialysis, affinity chromatography, e.g. on phenyl-agarose, specifically phenyl-sepharose, or ion-exchange chromatography, specifically on a MONO-Q- and/or MONO-S-matrix (Pharmacia, Uppsala, Sweden) or more specifically are those as described by Tavernier et al. [J. Mol. Biol. 211, 493-501 (1990)] and those disclosed in Example V.

It is therefore also an object of the present invention to provide a process for the preparation of hTNF muteins as specified above which process comprises cultivating a transformed host cell as described above in a suitable medium and isolating a mutein from the culture supernatant or the host cell itself, and if desired converting said mutein into a pharmaceutically acceptable salt. The compounds whenever prepared according to such a process are also an object of the present invention.

The hTNF muteins of the present invention are characterized by showing a selective binding affinity for the human p55-TNF-R. Such property can be determined by any assay known in the art measuring binding affinities. For example the binding of TNF itself and of the muteins of the present invention can be measured using cells in cell culture which express the two types of TNF-receptors to a different degree, like for example Hep-2 cells which exclusively express the human p55-TNF-R and U937 or HL60 cells which express in addition also the human p75-TNF-R [see Brockhaus et al., Proc. Nat. Acad. Sci. U.S.A. 87, 3127-3131, (1990); Hohmann et al., J. Biol. Chem. 264, 14927-14934, (1989); Loetscher et al. (1990); Dembic et al. (1990)]. Of course binding affinities can also be determined directly by using purified native or recombinant p55-TNF-R and p75-TNF-R as specifically described in the Examples, or by using the corresponding soluble analogs of such receptors.

The term selective binding affinity for the human p55-Tumor-Necrosis-Factor-Receptor" refers in the context of the present invention to a difference in binding affinities to the two types of TNF-receptors which is with respect to the used assay system significant enough to say that a mutein of the present invention binds selectively to the p55TNF-Receptors similar to wild-type TNF but has essentially lost functionally relevant binding to hp75-TNF-R. More specifically this term means in the context of the assay-system of the Examples that a  $K_D$ -value of a specific hTNF mutein of the present invention is at least a factor of 10 or more, especially preferred at least a factor of  $10^2$ , larger than for wild-type TNF- $\alpha$  determined by using the in vitro binding assay with recombinant soluble hp75-TNF-R whereas its  $K_D$ -value determined by using the in vitro binding assay to recombinant soluble hp55-TNF-R for the same hTNF mutein differs not by more than a factor of 2 from that of wild-type TNF- $\alpha$ . It is however understood that these specific  $K_D$ -values are given for illustration and should not be considered as limiting in any manner.

The hTNF muteins of the present invention can be characterized by their anti-tumour activity by methods known in the art.

The hTNF muteins may be administered alone or with one or more additional compounds of the present invention in pharmaceutically acceptable oral, injectable or topical compositions and modes. Administration will be in a dosage such that the amount of the composition in the patient is effective to modify the biological function associated with hTNF mutein function.

Pharmaceutical compositions containing hTNF muteins in association with a compatible pharmaceutically acceptable carrier material are therefore a further object of the present invention. Any conventional carrier material can be utilized. The carrier material can be an organic or inorganic one suitable for enteral, percutaneous or parenteral administration. Suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene-glycols, petroleum jelly and the like. Furthermore, the pharmaceutical preparations may contain other pharmaceutically active agents. Additional additives such as flavouring agents, preservatives, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding.

The pharmaceutical preparations can be made up in any conventional form including: a) a solid form of oral administration such as tablets, capsules, pills, powders, granules and the like; b) a liquid form for oral administration such as solutions, syrups, suspensions, elixirs and the like; c) preparations for parenteral administration such as sterile solutions, suspensions or emulsions; and d) preparations for topical administrations such as solutions, suspensions, ointments, creams, gels, micronized powders, aerosols and the like. The pharmaceutical preparations may be sterilized and/or may contain adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, salts for varying the osmotic pressure and/or buffers.

Parenteral dosage forms may be infusions or injectable solutions which can be injected intravenously or intramuscularly. These preparations can also contain other medicinally active substances. Additional

additives such as preservatives, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding.

Accordingly it is also an object of the present invention to provide a process for the preparation of a pharmaceutical composition which process is characterized in that a compound obtained by a process of the present invention and if desired, additional pharmaceutically active substances are mixed with a non-toxic, inert, therapeutically compatible carrier material and the mixture is brought into a galenical application form.

Furthermore the use of a compound prepared according to a process of the present invention for the preparation of a pharmaceutical composition as described above is also an object of the present invention.

Finally, antibodies can be raised against the hTNF muteins of the present invention. These antibodies can be used in a well-known manner for diagnostic or therapeutic purposes as well as for purification purposes. Such antibodies can be produced by injecting a mammalian or avian animal with a sufficient amount of a vaccine formulation comprising a hTNF mutein of the present invention and a compatible pharmaceutical carrier to elicit the production of antibodies against said hTNF mutein. The appropriate amount of the hTNF mutein which would be required would be known to one of skill in the art or could be determined by routine experimentation. As used in connection with this invention, the term "pharmaceutical carrier" can mean either the standard compositions which are suitable for human administration or the typical adjuvants employed in animal vaccinations.

TNF is a potent pleiotropic cytokine. Its many different activities such as, for example, the activity of growth factor for immune cells, mediator in inflammation, or inductor of specific genes in endothelium, may be seen in the context of host defense to infection and injury. TNF also exhibits high systemic toxicity; the deleterious effects of bacteraemia and septic shock or of bacterial meningitis are mediated to a large extent by endogenous cytokines among which TNF has an early and important role. Furthermore, many cells and cell lines are sensitive to a direct cytotoxic activity of TNF. Various systemic effects and cellular toxicity presumably combine in the antitumor activity of TNF seen in animal studies.

These facts form the rational basis for the development of novel therapeutic strategies using the hTNF muteins of the present invention, where in particular the potential to dissect the many different hTNF activities shall be fully exploited to separate unwanted toxic from desired activities. One example is to use the hTNF muteins of the present inventions as antitumor agents at the high doses which are made possible by the presumably lower systemic toxicity and thus to overcome the dose-limiting toxicity which presumably severely restricts the use of wild-type hTNF in cancer patients. However, the potential use of the hTNF muteins of the present invention is not restricted to cancer therapy. Any disease where TNF as host defense factor in bacterial infection [for example Kindler, V. et al., CELL 56, 731-740 (1989); Nakano, Y. et al., J. Immunol. 144, 1935, (1990)] or as mediator in inflammation plays a beneficial role might benefit from a 55kDa TNF receptor type specific drug such as the hTNF muteins of the present invention. TNF has also been shown to play a role in cachexia [eg. Beutler, B. and Cerami, (sa)] and TNF muteins of the present invention with low systemic toxicity might be used for anti-obesity therapy. Even disease states characterised by the toxic activities exerted by excessive TNF release such as septic shock or bacterial meningitis can benefit from 55kDa TNF receptor specific agonists such as the muteins of the present invention above or in combination with TNF antagonists

A concise summary of the emerging role of TNF for novel therapies, where p55-TNF-Receptor type specific agonists of lower systemic toxicity and selectively triggering only some of the many different TNF activities may be expected to have significant advantages when compared to wild-type TNF, has been published [Tumor Necrosis Factors, The Molecules and their Emerging Role in Medicine, B. Beutler, ed., Raven Press, 1992, ISBN 0-88167-852-X]. It includes the activities of TNF in modulating endothelial cell homostatic properties and neutrophil adhesion, tissue ischemia and reperfusion injury, on osteoblasts and osteoclasts in bone resorption, as growth factor on many cells in general and in hematopoiesis, as well as in metabolic and nutritional effects. The induction of specific genes providing cellular protection mechanisms such as induction of Mn-superoxide dismutase known to be under the control of p55-TNFR [Lewis et al, Proc. Natl. Acad. Sci. USA 88, 2830 (1991); Tartaglia et al, Proc. Natl. Acad. Sci. USA 88, 9292 (1991)] or the direct cytotoxicity of TNF in some cells all provide a rational base for novel therapeutic strategies using receptor type specific TNF agonists. TNF as growth/differentiation factor in the generation of lymphokine-activated killer (LAK) cells appears to contribute to the antitumor activities of TNF.

An important aspect is that all these activities may be enhanced or modulated in combination with other recombinant cytokines such as for example interferon-gamma.

After the invention has been described in general hereinbefore, the following Examples are intended to illustrate details of the invention, without thereby limiting it in any manner, in connection with the following Figures:



The following abbreviations and symbols used are: B, E, H, S, Xb and X which indicate cleavage sites for restriction enzymes BglI, EcoRI, HindIII, Sall, XbaI and XhoI, respectively.



represents the regulatable promoter/operator element N25OPSN25OP29,



represents the synthetic ribosomal binding site RBSII, SphI,



represents genes for TNF $\alpha$  (TNF $\alpha$ ),  $\beta$ -lactamase (bla), chloramphenicol acetyltransferase (cat), lac repressor (lacI) and neomycin phosphotransferase (neo),



represents transcriptional terminators t<sub>0</sub> of phage lambda (t<sub>0</sub>) and T1 of the E. coli rrnB operon (T1)  $\rightleftharpoons$

represents the replication regions of plasmids pBR322 and pREP4 (repl.),  $\rightarrow$  represents the coding region under control of N25OPSN25OP29 and RBSII, SphI.

- 25 Figure 1a is a schematic drawing of the plasmid pDS56/RBSII, SphI-TNF $\alpha$ .  
 Figure 1b displays the complete nucleotide sequence of plasmid pDS56/RBSII, SphI-TNF $\alpha$ . In this sequence, the recognition sequences of the restriction enzymes depicted in Figure 1a are indicated. The amino acid sequence shown represents in the three letter code the sequence of the mature TNF $\alpha$  (157 amino acids).  
 30 Figure 2a is a schematic drawing of the plasmid pREP4.  
 Figure 2b displays the complete nucleotide sequence of plasmid pREP4. In this sequence, the recognition sequences of the restriction enzymes depicted in Figure 2a are indicated.  
 Figure 3 outlines the preparation of an EcoRI-HindIII fragment encoding the TNF $\alpha$  mutants Thr<sup>86</sup>-TNF $\alpha$ .  
 35 Figure 4 displays the nucleotide sequence of Fragment 1 of plasmid pDS56/RBSII, SphI-INF $\alpha$ -(Trp32)  
 Figure 5 displays the nucleotide sequence of Fragment 1 of plasmid "pDS56/RBSII, SphI-TNF $\alpha$ -(Ser29)  
 40 Figure 6 displays the nucleotide sequence of Fragment 1 of plasmid pDS56/RBSII, SphI-TNF $\alpha$ -(Ser29Trp32)  
 Figure 7 Competitive binding of wild-type human TNF $\alpha$  and Thr<sup>86</sup>, Trp<sup>32</sup>-Thr<sup>86</sup> and Ser<sup>29</sup>-Trp<sup>32</sup>-Thr<sup>86</sup> muteins to recombinant human p-75 and p-55 TNF-R's.  
 45 Microtiter plates coated with recombinant human p-75TNF-R-IgG $\gamma$ 3 fusion protein (panel A) and recombinant human p-55TNF-R-IgG $\gamma$ 3 fusion protein (panel B) were incubated with radiolabelled human TNF $\alpha$  in the presence of different concentrations of wild-type TNF $\alpha$  - (closed circles), Thr<sup>86</sup> mutein (open circles), Trp<sup>32</sup>-Thr<sup>86</sup> mutein (open squares) and Ser<sup>29</sup>-Trp<sup>32</sup>-Thr<sup>86</sup> mutein (open triangles). After three hours at room temperature bound radioactivity was counted in a  $\gamma$ -counter.  
 50 Figure 8 Competitive binding of wild-type human TNF $\alpha$  and Ser<sup>29</sup>-Thr<sup>86</sup>, Glu<sup>31</sup>-Thr<sup>86</sup> and Asn<sup>31</sup>-Thr<sup>32</sup>-Thr<sup>86</sup> muteins to recombinant human p-75 and p-55TNF-R's.  
 55 Microtiter plates coated with recombinant human p-75TNF-R-IgG $\gamma$ 3 fusion protein (panel A) and recombinant human p-55TNF-R-IgG $\gamma$ 3 fusion protein (panel B) were incubated with radiolabelled human TNF $\alpha$  in the presence of different concentrations of wild-type TNF $\alpha$  - (closed circles), Ser<sup>29</sup>-Thr<sup>86</sup> mutein (open circles), Asn<sup>31</sup>-Thr<sup>32</sup>-Thr<sup>86</sup> mutein (open squares) and Glu<sup>31</sup>-Thr<sup>86</sup> mutein (open triangles). After three hours at room temperature bound radioactivity was counted in a  $\gamma$ -counter.

Unless otherwise specified, percentages given below for solids in solid mixtures, liquids in liquids and solids in liquids are on a wt/wt, vol/vol and wt/vol basis, respectively.

#### Example I

#### Preparation of Thr<sup>86</sup>-TNF $\alpha$

#### Plasmid pDS56/RBSII,SphI-TNF $\alpha$

The human TNF $\alpha$  expression plasmid pDS56/RBSII,SphI-TNF $\alpha$  (see Figure 1) was the source of the TNF $\alpha$  gene for preparation of the various TNF $\alpha$  muteins of this invention. The transformed E. coli strain M15 [pREP4;pDS56/RBSII,SphI-TNF $\alpha$ ] has been deposited under the Budapest Treaty for patent purposes at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) in Braunschweig, BRD, at September 8th, 1991, under the accession number DSM 6713.

#### Mutagenesis of the TNF $\alpha$ gene using PCR

Two PCR reactions were performed with plasmid pDS56/RBSII,SphI-TNF $\alpha$  (Figure 1) as the template DNA using a Perkin-Elmer Cetus GeneAmp™ DNA Amplification Reagent Kit with AmpliTaq™ Recombinant Taq DNA Polymerase [see Figure 3].

Reaction I was performed with primers 17/F (5'-GGCGTATCACGAGGCCCTTTCG-3'; primer 17/F comprises nucleotides 3949-3970 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ ) and 29/M22 (5'-GTAGGTGACGGCGATGCGGCTGATGGT-3'; primer 29/M22 comprises nucleotides which are complementary to nucleotides 378-352 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ , the mutated base is underlined).

Reaction II was performed with primers 29/MR1 (5'-CAGACCAAGGTCAACCTCCTC-3'; primer 29/MR1 comprises nucleotides 379-399 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ ) and 17/O (5'-CATTACTGGATCTATCAACAGG-3'; primer 17/O comprises nucleotides which are complementary to nucleotides 748-727 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ ).

In a typical experiment, 10  $\mu$ l template DNA (10 ng), 5  $\mu$ l each of the two primers (100 pmoles each), 16  $\mu$ l dNTP's mix (1.25 mM of dATP, dGTP, dCTP, and dTTP), 10  $\mu$ l 10x reaction buffer (100 mM Tris-HCl pH8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub> and 0.1 % gelatin), 1  $\mu$ l (5 units) AmpliTaq™ DNA polymerase and 53  $\mu$ l H<sub>2</sub>O were mixed in an Eppendorf tube and overlaid with 80  $\mu$ l mineral oil (Perkin-Elmer Cetus). The tubes were transferred to a DNA thermal cycler (TRIO-Thermoblock, Biometra) and kept for 1 min at 94°C, before 35 cycles of melting the DNA (1 min at 94°C), annealing the primers (1 min at 50°C), and extending the primers (3 min at 72°C) were performed. After additional 2 min at 72°C, the reactions were cooled to room temperature and extracted with chloroform. The DNA present in the aqueous phase was precipitated with ethanol and subjected to electrophoresis in a 6 % polyacrylamide gel [Sambrook et al., 1989]. After staining of the DNA with ethidium bromide, fragments I and II (see Figure 3) were isolated from the gel and purified [Sambrook et al., 1989].

#### Preparation of a DNA fragment encoding Thr<sup>86</sup>-TNF $\alpha$

Fragments I and II were enzymatically phosphorylated, before they were ligated with each other [Sambrook et al., 1989]. After heat-inactivation of the ligase and digestion with restriction enzymes EcoRI and HindIII, the DNA was subjected to electrophoresis in a 6 % polyacrylamide gel. After staining of the DNA with ethidium bromide, the EcoRI-HindIII fragment A [see Figure 3] was isolated from the gel and purified [s.a].

#### Preparation of a plasmid encoding Thr<sup>86</sup>-TNF $\alpha$

The EcoRI-HindIII fragment A was inserted according to standard methods [Sambrook et al., 1989] into the EcoRI-HindIII opened plasmid pDS56/RBSII,SphI-TNF $\alpha$  generating the plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Thr86). Plasmid DNA was prepared [Birnboim et al., 1979] and the identity of the coding region for the TNF $\alpha$  mutein was confirmed by sequencing the double-stranded DNA [Sambrook et al., 1989].

Production of Thr<sup>86</sup>-TNF $\alpha$ 

Plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Thr86) was transformed into E. coli M15 cells containing already plasmid pREP4 by standard methods [s.a.]. Transformed cells were grown at 37°C in LB medium [Sambrook et al., 1989] containing 100 mg/l ampicillin and 25 mg/l kanamycin. At an optical density at 600 nm of about 0.7 to 1.0 IPTG was added to a final concentration of 2 mM. After additional 2.5 to 5 h at 37°C the cells were harvested by centrifugation.

## Example II

10

Preparation of Glu<sup>31</sup>-TNF $\alpha$  and Asn<sup>31</sup>Thr<sup>32</sup>-TNF $\alpha$ 

## Principles

15 The TNF $\alpha$  muteins Glu<sup>31</sup>-TNF $\alpha$  and Asn<sup>31</sup>Thr<sup>32</sup>-TNF $\alpha$  were prepared following the procedure described in detail in Example I for the preparation of Thr<sup>86</sup>-TNF $\alpha$ . Therefore, in the description of the preparation of the TNF $\alpha$  muteins listed above only the primers used in PCR reactions I and II are specified. Furthermore, the names of the expression plasmids encoding the various TNF $\alpha$  muteins are given.

20 Preparation of Glu<sup>31</sup>-TNF $\alpha$ 

PCR reaction I was performed with primers 17/F (5'-GGCGTATCACGAGGCCCTTTTCG-3'; primer 17/F comprises nucleotides 3949-3970 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ ) and 21/M5 (5'-ATTGGCCCGCTCGTTCAGCCACTGGAGCTGCCCCTC-3'; primer 21/M5 comprises nucleotides which are complementary to nucleotides 219-184 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ , mutated bases are underlined). PCR reaction II was performed with primers 21/MR (5'-GCCCTCCTGGCCAATGGCGTGG-3'; primer 21/MR comprises nucleotides 220-241 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ ) and 17/O (5'-CATTACTGGATCTATCAACAGG-3'; primer 17/O comprises nucleotides which are complementary to nucleotides 748-727 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ ).

30 The resulting expression plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Glu31) was used for production of Glu<sup>31</sup>-TNF $\alpha$  and in the construction of plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Glu31Thr86) (see Example IV).

Preparation of Asn<sup>31</sup>Thr<sup>32</sup>-TNF $\alpha$ 

35 PCR reaction I was performed with primers 17/F (5'-GGCGTATCACGAGGCCCTTTTCG-3'; primer 17/F comprises nucleotides 3949-3970 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ ) and 21/M6 (5'-ATTGGCAGTGTGTTTCAGCCACTGGAGCTGCCCCTC-3'; primer 21/M6 comprises nucleotides which are complementary to nucleotides 219-184 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ , mutated bases are underlined). PCR reaction II was performed with primers 21/MR (5'-GCCCTCCTGGCCAATGGCGTGG-3'; primer 21/MR comprises nucleotides 220-241 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ ) and 17/O (5'-CATTACTGGATCTATCAACAGG-3'; primer 17/O comprises nucleotides which are complementary to nucleotides 748-727 of plasmid pDS56/RBSII,SphI-TNF $\alpha$ ).

45 The resulting expression plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Asn31Thr32) was used for production of Asn<sup>31</sup>Thr<sup>32</sup>-TNF $\alpha$  and in the construction of plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Asn31Thr32Thr86) (see Example IV).

## Example III

Preparation of Trp<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$ 

50

## Principles

For preparation of Trp<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$  the expression plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Trp32Thr86) was constructed, which was subsequently used for the production of Trp<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$  in E. coli.

55

Construction of plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Trp32Thr86)

All the expression plasmids described in Examples I and II contain the same two sites for the restriction enzyme BglI as plasmid pDS56/RBSII,SphI-TNF $\alpha$  (see Figure 1). One of these sites is located in the  $\beta$ -lactamase gene whereas the other site is located in the TNF $\alpha$  gene. This latter site separates the coding region for TNF $\alpha$  into two parts: one part is coding for amino acids 1 to 36 of TNF $\alpha$ , the other part encodes amino acids 37 to 157 of TNF $\alpha$  (see Figure 1b).

For construction of plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Trp32Thr86) DNA fragments 1 and 2 were prepared according to standard methods [Sambrook et al., 1989]. Fragment 1 (for sequences see Fig. 4) was the small BglI fragment of plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Trp32) with the regulatable promoter and the coding region for Trp<sup>32</sup>-TNF $\alpha$  up to amino acid 36. Fragment 2 was the large BglI fragment of plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Thr86) with the coding region for Thr<sup>86</sup>-TNF $\alpha$  starting at amino acid 37 and the replication region of the plasmid. Fragment 1 and the enzymatically dephosphorylated fragment 2 were ligated with each other [Sambrook et al., 1989] resulting in plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Trp32Thr86).

M15(pREP4;pDS56/RBSII,SphI-TNF $\alpha$ (Trp32)) cells have been deposited under the Budapest Treaty for patent purposes at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) in Braunschweig, BRD at November 19th, 1990 under accession number DSM 6241.

Production of Trp<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$

Plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Trp32Thr86) was transformed into E. coli M15 cells containing already plasmid pREP4 by standard methods [s.a.]. Transformed cells were grown at 37°C in LB medium [s.a.] containing 100 mg/l ampicillin and 25 mg/l kanamycin. At an optical density at 600 nm of about 0.7 to 1.0 IPTG was added to a final concentration of 2 mM. After additional 2.5 to 5 h at 37°C the cells were harvested by centrifugation.

Example IV

Preparation of Ser<sup>29</sup>Thr<sup>86</sup>-TNF $\alpha$ , Ser<sup>29</sup>Trp<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$ , Glu<sup>31</sup>Thr<sup>86</sup>-TNF $\alpha$  and Asn<sup>31</sup>Thr<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$

Principles

The TNF $\alpha$  muteins Ser<sup>29</sup>Thr<sup>86</sup>-TNF $\alpha$ , Ser<sup>29</sup>Trp<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$ , Glu<sup>31</sup>Thr<sup>86</sup>-TNF $\alpha$  and Asn<sup>31</sup>Thr<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$  were prepared following the procedure described in detail in Example III for the preparation of Trp<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$ . Therefore, in the description of the preparation of the TNF $\alpha$  muteins listed above only the DNA fragments corresponding to fragment 1 of Example III are specified. Furthermore, the names of the expression plasmids encoding the various TNF $\alpha$  muteins are given.

Preparation of Ser<sup>29</sup>Thr<sup>86</sup>-TNF $\alpha$

Fragment 1 (for sequences see Fig. 5) was the small BglI fragment of plasmid pDS56/RBSII,SphI-TNF $\alpha$ -(Ser29) with the regulatable promoter and the coding region for Ser<sup>29</sup>-TNF $\alpha$  up to amino acid 36. Fragment 1 and the enzymatically dephosphorylated fragment 2 (see Example III) were ligated with each other [Sambrook et al., 1989] resulting in plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Ser29Thr86), which was subsequently used for the production of Ser<sup>29</sup>Thr<sup>86</sup>-TNF $\alpha$  in E. coli.

M15 (pREP4;pDS56/RBSII,SphI-TNF $\alpha$ (Ser29)) cells have been deposited under the Budapest Treaty for patent purposes at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) in Braunschweig, BRD at November 19th, 1990 under accession number DSM 6240.

Preparation of Ser<sup>29</sup>Trp<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$

Fragment 1 (for sequences see Fig. 6) was the small BglI fragment of plasmid pDS56/RBSII,SphI-TNF $\alpha$ -(Ser29Trp32) with the regulatable promoter and the coding region for Ser<sup>29</sup>Trp<sup>32</sup>-TNF $\alpha$  up to amino acid 36. Fragment 1 and the enzymatically dephosphorylated fragment 2 (see Example III) were ligated with each other [Sambrook et al., 1989] resulting in plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Ser29Trp32Thr86), which was subsequently used for the production of Ser<sup>29</sup>Trp<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$  in E. coli.

Preparation of Glu<sup>31</sup>Thr<sup>86</sup>-TNF $\alpha$ 

Fragment 1 was the small BglI fragment of plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Glu31) with the regulatable promoter and the coding region for Glu<sup>31</sup>-TNF $\alpha$  up to amino acid 36. Fragment 1 and the enzymatically dephosphorylated fragment 2 (see Example III) were ligated with each other [Sambrook et al., 1989]  
 5 resulting in plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Glu31Thr86), which was subsequently used for the production of Glu<sup>31</sup>Thr<sup>86</sup>-TNF $\alpha$  in E. coli.

Preparation of Asn<sup>31</sup>Thr<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$ 

10

Fragment 1 was the small BglI fragment of plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Asn31Thr32) with the regulatable promoter and the coding region for Asn<sup>31</sup>Thr<sup>32</sup>-TNF $\alpha$  up to amino acid 36. Fragment 1 and the enzymatically dephosphorylated fragment 2 (see Example III) were ligated with each other [Sambrook et al., 1989]  
 15 resulting in plasmid pDS56/RBSII,SphI-TNF $\alpha$ (Asn31Thr32Thr86), which was subsequently used for the production of Asn<sup>31</sup>Thr<sup>32</sup>Thr<sup>86</sup>-TNF $\alpha$  in E. coli.

Example VPurification of Human TNF $\alpha$  Muteins

20

One liter overnight cultures of E. coli cells transformed and induced as described above were collected by centrifugation and resuspended in 20 ml 50 mM Tris, pH 7.2, 200 mM KCl, 50 mM MgCl<sub>2</sub>, 5% glycerol. The cells were disrupted in a French press at a pressure of 20'000 psi. After clarification by centrifugation (70'000 x g, 30 min, 4°C) solid ammonium sulfate was added to a final concentration of 30%. The solution  
 25 was stirred at room temperature for one hour and then centrifuged at 10'000 x g for 20 min at 4°C. The supernatant was filtered through a 0.45 $\mu$ m filter and adjusted to 70% in ammonium sulfate. The precipitated proteins were collected by centrifugation, dissolved in 20 ml 20 mM Tris, pH 9.0, and dialyzed against the same buffer overnight at 4°C. 1 ml aliquots of the dialyzed samples were applied to a MonoQ column (HR 5/5, LKB-Pharmacia) equilibrated in 20 mM Tris pH 9.0 and eluted with a linear NaCl gradient (0 to 400 mM  
 30 in 20 mM Tris pH 9.0) at a flow rate of 0.5 ml/min. 0.5 ml fractions were collected and analyzed for the presence of TNF $\alpha$  muteins by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Positive fractions were pooled, dialyzed against 20 mM 2-morpholinoethanesulfonic acid (MES) pH 6.0 and applied to a MonoS column (HR 5/5, LKB-Pharmacia) equilibrated in 20 mM MES pH 6.0. Proteins were eluted with a linear NaCl gradient (0 to 400 mM in 20 mM MES pH 6.0) at a flow rate of 0.5 ml/min. The  
 35 various TNF $\alpha$  muteins eluted as electrophoretically pure proteins between 250 mM and 350 mM NaCl. After dialysis against phosphate buffered saline (PBS) the protein concentration was determined by the BCA Protein Assay (Pierce Chemical Company) using wild-type human TNF $\alpha$  as a standard.

Example VI

40

Competitive Binding of Human TNF $\alpha$  and Muteins to Recombinant Human p75-TNF-R and p55-TNF-R


For the competitive binding assay microtiter plates were coated with recombinant human p75-TNF-R-human IgG $\gamma$ 3 and p55-TNF-R-human IgG $\gamma$ 3 fusion proteins dissolved in PBS at 0.3  $\mu$ g/ml and 0.1  $\mu$ g/ml,  
 45 respectively, (100  $\mu$ l/well, overnight at 4°C) [Loetscher, H. et al., J. Biol. Chem. 266, 18324 - 18329 (1991); Lesslauer, W. et al., Eur. J. Immunol. 21, 2883 - 2886 (1991)]. After blocking with blocking buffer (50 mM Tris pH 7.4, 140 mM NaCl, 5 mM EDTA, 0.02% NaN<sub>3</sub>, 1% defatted milk powder) the microtiter plate was washed with PBS and incubated with 10 ng/ml human <sup>125</sup>I-TNF $\alpha$  (labelled by the Iodogen method (Pierce Chemical Company) to a specific activity of about 30  $\mu$ Ci/ $\mu$ g) in the presence of different concentrations of  
 50 the muteins. The volume was 100  $\mu$ l/well and each concentration was assayed in triplicate. After three hours at room temperature the wells were thoroughly washed with PBS and counted in a g-counter.

Claims

- 55 1. A human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof having selective binding affinity for the human p55-Tumor-Necrosis-Factor-Receptor characterized in that the amino acid sequence of human Tumor Necrosis Factor is changed at least at position 86 showing a threonine instead of a serine residue.

2. A mutein as claimed in claim 1 or a pharmaceutically acceptable salt thereof, wherein said amino acid sequence is changed at one or more additional positions, preferably at one or two additional positions.
3. A mutein as claimed in claim 2 or a pharmaceutically acceptable salt thereof, wherein said amino acid sequence is changed at positions 29 and 86, 31 and 86, 32 and 86, 29, 32 and 86, and 31, 32 and 86.
4. A mutein as claimed in any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof which is Thr<sup>86</sup>-TNF $\alpha$ , Ser<sup>29</sup>-Thr<sup>86</sup>-TNF $\alpha$ , Glu<sup>31</sup>-Thr<sup>86</sup>-TNF $\alpha$ , Trp<sup>32</sup>-Thr<sup>86</sup>-TNF $\alpha$ , Ser<sup>29</sup>-Trp<sup>32</sup>-Thr<sup>86</sup>-TNF $\alpha$  or Asn<sup>31</sup>-Thr<sup>32</sup>-Thr<sup>86</sup>-TNF $\alpha$ .
5. A DNA-sequence comprising a DNA-sequence coding for a mutein as claimed in any one of claims 1-4.
6. A vector, especially for expression in a prokaryotic or lower eukaryotic host cell, comprising a DNA-sequence as claimed in claim 5.
7. A host cell, especially a prokaryotic or lower eukaryotic host cell transformed with a vector as claimed in claim 6.
8. A host cell as claimed in claim 7 which is E. coli.
9. A compound as claimed in any one of claims 1-4 for the treatment of illnesses.
10. A process for the preparation of a compound as claimed in any one of claims 1-4 which process comprises cultivating a host cell as claimed in claim 7 or claim 8 in a suitable medium and isolating the mutein from the culture supernatant or the host cell itself, and if desired converting said mutein into a pharmaceutically acceptable salt.
11. A pharmaceutical composition which contains one or more compounds as claimed in any one of claims 1-4, if desired, in combination with additional pharmaceutically active substances and/or non-toxic, inert, therapeutically compatible carrier materials.
12. The use of a compound as claimed in any one of claims 1-4 for the treatment of illnesses.

Fig. 1a



16



Fig. 1b (cont.)

801 TTTTATTGG TGAGAATCCA AGCTAGCTTG GCGAGATTTT CAGGAGCTAA  
 851 GGAAGCTAAA ATGGAGAAAA AAATCACTGG ATATACCACC GTTGATATAT  
 901 CCCAATGGCA TCGTAAAGAA CATTTTGAGG CATTTTCAGTC AGTTGCTCAA  
 951 TGTACCTATA ACCAGACCGT TCAGCTGGAT ATTACGGCCT TTTTAAAGAC  
 1001 CGTAAAGAAA AATAAGCACA AGTTTATCC GGCCTTTATT CACATTCCTG  
 1051 CCGCCTGAT GAATGCTCAT CCGGAATTC GTATGGCAAT GAAAGACCGT  
 1101 GAGCTGGTGA TATGGGATAG TGTTCACCCT TGTTACACCG TTTTCCATGA  
 1151 GCAAACGTAA ACGTTTTTCAT CGCTCTGGAG TGAATACCAC GACGATTTCC  
 1201 GGCAGTTTCT ACACATATAT TCGCAAGATG TGGCGTGTTA CCGTGAAAAC  
 1251 CTGGCCTATT TCCCTAAAGG GTTATTGAG AATATGTTTT TCGTCTCAGC  
 1301 CAATCCCTGG GTGAGTTTCA CCAGTTTGA TTAAACGTG GCCAATATGG  
 1351 ACAACTTCTT CGCCCCGTT TTCACCATGG GCAAATATTA TACGCAAGGC  
 1401 GACAAGGTGC TGATGCCGCT GCGGATTCAG GTTCATCATG CCGTCTGTGA  
 1451 TGGCTTCCAT GTCGGCAGAA TGCTTAATGA ATTACAACAG TACTGCGATG  
 1501 AGTGGCAGGG CGGGGCGTAA TTTTTTTAAG GCAGTTATTG GTGCCCTTAA  
 1551 ACGCCTGGGG TAATGACTCT CTAGCTTGAG GCATCAAATA AAACGAAAGG  
 1601 CTCAGTCGAA AGACTGGGCC TTTCGTTTGA TCTGTTGTTT GTCGGTGAAC  
 1651 GCTCTCTGA GTAGGACAAA TCCGCCGCTC TAGAGCTGCC TCGCGGTTTT  
 1701 CCGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG GAGACGGTCA  
 1751 CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG  
 1801 TCAGCGGGTG TTGGCGGGTG TCGGGGCGCA GCCATGACCC AGTCACGTAG  
 1851 CGATAGCGGA GTGTATACTG GCTTAACTAT GCGGCATCAG AGCAGATTGT  
 1901 ACTGAGAGTG CACCATATGC GGTGTGAAAT ACCGCACAGA TCGGTAAGGA  
 1951 GAAAATACCG CATCAGGCGC TCTTCGCTT CCTCGCTCAC TGA CTGCTG  
 2001 CGCTCGGTCT GTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT  
 2051 AATACGGTTA TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG  
 2101 CAAAAGGCCA GCAAAGGCC AGGAACCGTA AAAAGGCGC GTTGCTGGCG

XbaI

Fig. 1b (cont.)

2151 TTTTTCATA GGCTCCGCCC CCCTGACGAG CATCACAAAA ATCGACGCTC  
 2201 AAGTCAGAGG TGGCGAAACC CGACAGGACT ATAAAGATAC CAGGCGTTTC  
 2251 CCCCCTGAAG CTCCCTCGTG CGCTCTCTTG TTCCGACCCT GCCGCTTACC  
 2301 GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG  
 2351 CTCACGCTGT AGGTATCTCA GTTCGGTGTA GGTGCTTCGC TCCAAGCTGG  
 2401 GCTGTGTGCA CGAACCCCCC GTTCAGCCCG ACGGCTGCGC CTTATCCGGT  
 2451 AACTATCGTC TTGAGTCCAA CCCGGTAAGA CACGACTTAT CGCCACTGGC  
 2501 AGCAGCCACT GGTAACAGGA TTAGCAGAGC GAGGTATGTA GGCGGTGCTA  
 2551 CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG AAGGACAGTA  
 2601 TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG  
 2651 TAGCTCTTGA TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTTG  
 2701 TTTGCAAGCA GCAGATTACG CGCAGAAAAA AAGGATCTCA AGAAGATCCT  
 2751 TTGATCTTTT CTACGGGGTC TGACGCTCAG TGGAACGAAA ACTCACGTTA  
 2801 AGGGATTTTG GTCATGAGAT TATCAAAAAG GATCTTCACC TAGATCCTTT  
 2851 TAAATTAAAA ATGAAGTTTT AAATCAATCT AAAGTATATA TGAGTAAACT  
 2901 TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGOGAT  
 2951 CTGTCTATTT CGTTCATCCA TAGCTGCCTG ACTCCCCGTC GTGTAGATAA  
 3001 CTACGATACG GGAGGGCTTA CCATCTGGCC CCAGTGCTGC AATGATACCG  
 3051 CGAGACCCAC GCTCACCGGC TCCAGATTTA TCAGCAATAA ACCAGCCAGC  
 BglI  
 3101 CGGAAGGGCC GAGCGCAGAA GTGGTCCTGC AACTTATATCC GCCTCCATCC  
 3151 AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT  
 3201 AGTTTGCGCA ACGTTGTTGC CATTGCTACA GGCACTGTGG TGTCACGCTC  
 3251 GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG  
 3301 TTACATGATC CCCCATGTTG TGCAAAAAAG CGGTTAGCTC CTTGGGTCCT  
 3351 CCGATCGTTG TCAGAAGTAA GTTGGCCGCA GTGTTATCAC TCATGGTTAT  
 3401 GGCAGCACTG CATAATTCTC TTAGTGTGAT GCCATCCGTA AGATGCTTTT  
 3451 CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA GTGTATGCGG

Fig. 1b (cont.)

3501 CGACCGAGTT GCTCTTGCCC GCGTCAATA CCGGATAATA CCGCGCCACA  
3551 TAGCAGAACT TTAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA  
3601 AACTCTCAAG GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT  
3651 CGTGCACCCA ACTGATCTTC AGCATCTTTT ACTTTCACCA GCGTTTCTGG  
3701 GTGAGCAAAA ACAGGAAGGC AAAATGCCGC AAAAAAGGGA ATAAGGGCGA  
3751 CACGGAAATG TTGAATACTC ATACTCTTCC TTTTCAATA TTATTGAAGC  
3801 ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTG AATGTATTTA  
3851 GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC  
3901 CTGACGTCTA AGAAACCATT ATTATCATGA CATTAACCTA TAAAAATAGG  
3951 CGTATCACGA GGCCCTTTCG TCTTCAC

Fig. 2a




Fig. 2b

HindIII

```

1  AAGCTTCACG CTGCCGCAAG CACTCAGGGC GCAAGGGCTG CTAAAGGAAG
51 CGGAACACGT AGAAAGCCAG TCCGCAGAAA CGGTGCTGAC CCCGGATGAA
101 TGTCACTAC TGGGCTATCT GGACAAGGGA AAACGCAAGC GCAAAGAGAA
151 AGCAGGTAGC TTGCAGTGGG CTTACATGGC GATAGCTAGA CTGGGCGGTT
201 TTATGGACAG CAAGCGAACC GGAATTGCCA GCTGGGGCGC CCTCTGGTAA
251 GGTGGGAAG CCCTGCAAAG TAACTGGAT GGCTTTCTTG CCGCCAAGGA
301 TCTGATGGCG CAGGGGATCA AGATCTGATC AAGAGACAGG ATGACGGTCG
351 TTTCGCATGC TTGAACAAGA TGGATTGCAC GCAGGTTCTC CGGCCGCTTG
401 GGTGGAGAGG CTATTCGGCT ATGACTGGGC ACAACAGACA ATCGGCTGCT
451 CTGATGCCGC CGTGTTCCGG CTGTCAGCGC AGGGGCGCCC GGTCTTTTTT
501 GTCAAGACCG ACCTGTCCGG TGCCCTGAAT GAACTGCAGG ACCAGGCAGC
551 GCGGCTATCG TGGCTGGCCA CGACGGGCGT TCCTTGCGCA GCTGTGCTCG
601 ACGTTGTCAC TGAAGCGGGA AGGGACTGGC TGCTATTGGG CGAAGTGCCG
651 GGGCAGGATC TCCTGTGATC TCACCTTGCT CCTGCCGAGA AAGTATCCAT
701 CATGGCTGAT GCAATGCCGC GGCTGCATAC GCTTGATCCG GCTACCTGCC
751 CATTGACCA CCAAGCGAAA CATCGCATCG AGCGAGCAG TACTCGGATG
801 GAAGCCGGTC TTGTGATCA GGATGATCTG GACGAAGAGC ATCAGGGGCT
851 CGCGCCAGCC GAACTGTTG CCAGGCTCAA GGGCGCATG CCGACGGCG
901 AGGATCTCGT CGTGACCCAT GGGATGCCT GCTTGCCGAA TATCATGGTG
951 GAAAATGGCC GCTTTTCTGG ATTCAATGAC TGTGGCCGGC TGGGTGTGGC
1001 GGACCGCTAT CAGGACATAG CGTTGGCTAC CCGTGATATT GCTGAAGAGC
1051 TTGGCGGCGA ATGGGCTGAC CGCTTCCTCG TGCTTTACGG TATCGCCGCT
1101 CCCGATTGCG AGCGCATCGC CTTCTATCGC CTTCTTGACG AGTTCTTCTG
1151 AGCGGGACTC TGGGGTTGGA AATGACCGAC CAAGCGACGC CCAACCTGCC
1201 ATCAAGAGAT TTCGATTCCA CCGCCGCCTT CTATGAAAGG TTGGGCTTCG
1251 GAATCGTTTT CCGGGACGCC GGCTGGATGA TCCTCCAGCG CGGGGATCTC
1301 ATGCTGGAGT TCTTCGCCCC CCGGGGCTC GATCCCCTCG CGAGTTGGTT

```

Fig. 2b (cont.)

1351 CAGCTGCTGC CTGAGGCTGG ACGACCTCGC GGAGTTCTAC CGGCAGTGCA  
 1401 AATCCGTCGG CATCCAGGAA ACCAGCAGCG GCTATCCGCG CATCCATGCC  
 1451 CCCGAAGTGC AGGAGTGGGG AGGCACGATG GCGGCTTTGG TCGACAATTC  
 1501 GCGCTAACTT ACATTAATTG CGTTGCGCTC ACTGCCCCGT TTCCAGTCCG  
 1551 GAAACCTGTC GTGCCAGCTG CATTAAATGAA TCGGCCAACG CGCGGGGAGA  
 1601 GGCGGTTTGC GTATTGGGCG CCAGGGTGGT TTTTCTTTTC ACCAGTGAGA  
 1651 CGGGCAACAG CTGATTGCCC TTCACCGCCT GGCCCTGAGA GAGTTGCAGC  
 1701 AAGCGGTCCA CGCTGGTTTG CCCAGCAGG CGAAAATCCT GTTTGATGGT  
 1751 GGTTAACGGC GGGATATAAC ATGAGCTGTC TTCGGTATCG TCGTATCCCA  
 1801 CTACCGAGAT ATCCGCACCA ACGCGCAGCC CGGACTCGGT AATGGCGCGC  
 1851 ATTCGCCCCA GCGCCATCTG ATCGTTGGCA ACCAGCATCG CAGTGGGAAC  
 1901 GATGCCCTCA TTCAGCATTT GCATGGTTTG TTGAAAACCG GACATGGCAC  
 1951 TCCAGTCGCC TTCCCGTTCC GCTATCGGCT GAATTTGATT GCGAGTGAGA  
 2001 TATTTATGCC AGCCAGCCAG ACGCAGACGC GCCGAGACAG AACTTAATGG  
 2051 GCGCGTAAC AGCGCGATTT GCTGGTGACC CAATGCGACC AGATGCTCCA  
 2101 CGCCAGTCG CGTACCGTCT TCATGGGAGA AAATAATACT GTTGATGGGT  
 2151 GTCTGGTCAG AGACATCAAG AAATAACGCC GGAACATTAG TGCAGGCAGC  
 2201 TTCCACAGCA ATGGCATCCT GGTCATCCAG CGGATAGTGA ATGATCAGCC  
 2251 CACTGACGCG TTGCGCGAGA AGATTGTGCA CCGCGGCTTT ACAGGCTTCG  
 2301 ACGCGGCTTC GTTCTACCAT CGACACCACC ACGCTGGCAC CCAGTTGATC  
 2351 GGCGCGAGAT TTAATCGCG CGACAATTG CGACGGGCGG TGCAGGGCCA  
 2401 GACTGGAGGT GGCAACGCCA ATCAGCAACG ACTGTTTGCC CGCCAGTTGT  
 2451 TGTCACAGCG GGTGGGAAT GTAATTCAGC TCCGCCATCG CCGCTTCCAC  
 2501 TTTTCCCGC GTTTTCGAG AAACGTGGCT GGCCTGGTTC ACCACGCGGG  
 2551 AAACGGTCTG ATAAGAGACA CCGGCATACT CTGCGACATC GTATAACGTT  
 2601 ACTGGTTTCA CATTCACCAC CCTGAATTGA CTCTCTCCG GCGCTATCA  
 2651 TGCCATACCG CGAAGGTTT TGCGCCATTC GATGGTGTCA ACGTAAATGC

Fig. 2b (cont.)

SalI

```

2701 ATGCCGCTTC GCCTTCGCGC GCGAATTGTC GACCCCTGTCC CTCCTGTTCA
2751 GCTACTGACG GGGTGGTGCG TAACGGCAAA AGCACCGCCG GACATCAGCG
2801 CTAGCGGAGT GTATACTGGC TTAATATGTT GGCAC TGATG AGGGTGTCAG
2851 TGAAGTGCTT CATGTGGCAG GAGAAAAAAG GCTGCACCGG TCGGTCAGCA
2901 GAATATGTGA TACAGGATAT ATTCCGCTTC CTCGCTCACT GACTCGCTAC
2951 GCTCGGTGCT TCGACTGCGG CGAGCGGAAA TGGCTTACGA ACGGGGCGGA
3001 GATTTCTCTG AAGATGCCAG GAAGATACTT AACAGGGAAG TGAGAGGGCC
3051 GCGGCAAAGC CGTTTTTCCA TAGGCTCCGC CCCCTGACA AGCATCACGA
3101 AATCTGACGC TCAAATCAGT GGTGGCGAAA CCCGACAGGA CTATAAAGAT
3151 ACCAGGCGTT TCCCCTGGCG GCTCCCTCGT GCGCTCTCCT GTTCCTGCCT
3201 TTCGGTTTAC CGGTGTCAAT CCGCTGTAT GCGCGGTTT GTCTCATTC
3251 ACGCCTGACA CTCAGTTCCG GGTAGGCAGT TCGCTCCAAG CTGGACTGTA
3301 TGCACGAACC CCCCGTTTCA TCCGACCGCT GCGCCTTATC CGGTAACTAT
3351 CGTCTTGAGT CCAACCCGGA AAGACATGCA AAAGCACCAC TGGCAGCAGC
3401 CACTGGTAAT TGATTTAGAG GAGTTAGTCT TGAAGTCATG CGCCGGTTAA
3451 GGCTAAACTG AAAGGACAAG TTTTGGTGAC TCGCTCCTC CAAGCCAGTT
3501 ACCTCGGTTT AAAGAGTTGG TAGCTCAGAG AACCTTCGAA AAACCGCCCT
3551 GCAAGGCGGT TTTTTCGTTT TCAGAGCAAG AGATTACGG CAGACCAAAA
3601 CGATCTCAAG AAGATCATCT TATTAATCAG ATAAAAATTT TCTAGATTTT
3651 AGTGCAATTT ATCTCTTCAA ATGTAGCACC TGAAGTCAGC CCCATACGAT
3701 ATAAGTTGTT AATTCTCATG TTTGACAGCT TATCATCGAT

```

Fig. 3






Fig. 4

BglI

3102 GGAAGGGCC GAGCGCAGAA GTGGTCCTGC AACTTTATCC GCCTCCATCC

3151 AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT

3201 AGTTTGCGCA ACGTTGTTC CATTCCTACA GGCATCGTGG TGTACGGCTC

3251 GTGGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG

3301 TTACATGATC CCCCATGTTG TGCAAAAAG CGGTTAGCTC CTTGGGTCCT

3351 CCGATCGTTG TCAGAAGTAA GTTGGCCGCA GTGTTATCAC TCATGGTTAT

3401 GGCAGCACTG CATAATCTC TTAATGTCAT GCCATCCGTA AGATGCTTTT

3451 CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA GTGTATGCGG

3501 CGACCGAGTT GCTCTTGCCC GCGTCAATA CGGGATAATA CCGCGCCACA

3551 TAGCAGAACT TTAAAAGTGC TCATCATTCG AAAACGTTCT TCGGGGCGAA

3601 AACTCTCAAG GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT

3651 CGTGCACCCA ACTGATCTTC AGCATCTTTT ACTTTCACCA GCGTTTCTGG

3701 GTGAGCAAAA ACAGGAAGGC AAAATGCCGC AAAAAAGGGA ATAAGGGCGA

3751 CACGGAAATG TTGAATACTC ATACTCTTCC TTTTTCATA TTATTGAAGC

3801 ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTG AATGTATTTA

3851 GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCTCGA AAAGTGCCAC

3901 CTGACGTCTA AGAAACCATT ATTATCATGA CATTAACCTA TAAAAATAGG

3951 CGTATCACGA GGCCCTTTGG TCTTCAC-

XhoI

1 -CTCGAGAAAT CATAAAAAT TTATTGCTT TGTGAGCGGA TAACAATTAT

EcoRI

51 AATAGATTCA ATTGTGAGCG GATAACAATT TCACACAGAA TTCATTAAAG

101 AGGAGAAATT AAGCATGGTC AGATCATCTT CTCGAACCCC GAGTGACAAG

Val ArgSerSerS erArgThrPr oSerAspLys

1 11

151 CCTGTAGCCC ATGTTGTAGC AAACCTCAA GCTGAGGGGC AGCTCCAGTG

ProValAlaH isValValAl aAsnProGln AlaGluGlyG lnLeuGlnTr

21

BglI

201 GCTGAACCGC TGGGCCAATG CCCTCCTGGC

pLeuAsnArg TrpAlaAsnA laLeu

31 36

Fig. 5

BglI

3102 GGAAGGGCC GAGCGCAGAA GTGGTCCTGC AACTTTATCC GCCTCCATCC

3151 AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT

3201 AGTTTGCGCA ACGTTGTTGC CATTGCTACA GGCATCGTGG TGTCACGCTC

3251 GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG

3301 TTACATGATC CCCCATGTTG TGCAAAAAAG CGGTTAGCTC CTTCGGTCCT

3351 CCGATCGTTG TCAGAAGTAA GTTGGCCGCA GTGTTATCAC TCATGGTTAT

3401 GGCAGCACTG CATAATTCTC TTAGTGTATC GCCATCCGTA AGATGCTTTT

3451 CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA GTGTATGCGG

3501 CGACCGAGTT GCTCTTGCCC GCGTCAATA CGGGATAATA CCGCGCCACA

3551 TAGCAGAACT TAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA

3601 AACTCTCAAG GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT

3651 CGTGCAACCA ACTGATCTTC AGCATCTTTT ACTTTCACCA GCGTTTCTGG

3701 GTGAGCAAAA ACAGGAAGGC AAAATGCCG AAAAAGGGA ATAAGGGCGA

3751 CAAGGAAATG TTGAATACTC ATACTCTTCC TTTTCAATA TTATTGAAGC

3801 ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTG AATGTATTTA

3851 GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCGA AAAGTCCAC

3901 CTGACGTCTA AGAAACCATT ATTATCATGA CATTAACCTA TAAAAATAGG

3951 CGTATCACGA GGCCCTTTGG TCTTCAC-

XhoI

1 -CTCGAGAAAT CATAAAAAAT TTATTGCTT TGTGAGCGGA TAACAATTAT

EcoRI

51 AATAGATTCA ATTGTGAGCG GATAACAATT TCACACAGAA TTCATTAAAG

101 AGGAGAAATT AAGCATGGTC AGATCATCTT CTCGAACCCC GAGTGACAAG

Val ArgSerSerS erArgThrPr oSerAspLys

1 11

151 CCGTAGCCCC ATGTTGTAGC AAACCTCAA GCTGAGGGGC AGCTCCAGTG

ProValAlaH isValValAl aAsnProGln AlaGluGlyG InLeuGlnTr

21

BglI

201 GTCCAACCGC CGGGCCAATG CCCTCCTGGC

pSerAsnArg ArgAlaAsnA laLeu

31 36

Fig. 6

BglI

3102 GGAAGGGCC GAGCGCAGAA GTGGTCCTGC AACTTTATCC GCCTCCATCC

3151 AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC GCCAGTTAAT

3201 AGTTTGCGCA ACGTTGTTGC CATTGCTACA GGCATCGTGG TGTACGCTC

3251 GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG

3301 TTACATGATC CCCCATGTTG TGCAAAAAG CGGTAGCTC CTTCGGTCCT

3351 CCGATCGTTG TCAGAAGTAA GTTGGCCGCA GTGTTATCAC TCATGGTTAT

3401 GGCAGCACTG CATAATTCTC TTAGTGTATC GCCATCCGTA AGATGCTTTT

3451 CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA GTGTATGCGG

3501 CGACCGAGTT GCTCTTGCCC GCGGTCAATA CGGGATAATA CCGCGCCACA

3551 TAGCAGAACT TTAAAAGTGC TCATCATTTG AAAACGTTCT TCGGGGCGAA

3601 AACTCTCAAG GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT

3651 CGTGCACCCA ACTGATCTTC AGCATCTTTT ACTTTCACCA GCGTTTCTGG

3701 GTGAGCAAAA ACAGGAAGGC AAAATGCCGC AAAAAAGGA ATAAGGGCGA

3751 CACGGAAATG TTGAATACTC ATACTCTTCC TTTTTCATA TTATTGAAGC

3801 ATTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG AATGTATTTA

3851 GAAAAATAAA CAAATAGGGG TTCGCGCAC ATTTCCCCGA AAAGTGCCAC

3901 CTGACGTCTA AGAAACCATT ATTATCATGA CATTAACTA TAAAAATAGG

3951 CGTATCACGA GGCCCTTTCTG TCTTCAC-

XhoI

1 -CTCGAGAAAT CATAAAAAAT TTATTGCTT TGTGAGCGGA TAACAATTAT

EcoRI

51 AATAGATTCA ATTGTGAGCG GATAACAATT TCACACAGAA TTCATTAAAG

101 AGGAGAAATT AAGCATGGTC AGATCATCTT CTCGAACCCC GAGTGACAAG

Val ArgSerSerS erArgThrPr oSerAspLys  
1 11

151 CCTGTAGCCC ATGTTGTAGC AAACCCTCAA GCTGAGGGGC AGCTCCAGTG

ProValAlaH isValValAl aAsnProGln AlaGluGlyG lnLeuGlnTr  
21

BglI

201 GTCCAACCGC TGGGCCAATG CCTCCTGGC

pSerAsnArg TrpAlaAsnA laLeu

31

36

Figure 7







Figure 8



(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number: **0 563 714 A3**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: **93104591.8**

(51) Int. Cl.<sup>5</sup>: **C12N 15/28, C12P 21/02,  
C07K 13/00, C12N 1/21,  
A61K 37/02**

(22) Date of filing: **20.03.93**

(30) Priority: **02.04.92 EP 92810249**

(43) Date of publication of application:  
**06.10.93 Bulletin 93/40**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC  
NL PT SE**

(88) Date of deferred publication of the search report:  
**10.11.93 Bulletin 93/45**

(71) Applicant: **F. HOFFMANN-LA ROCHE AG  
Postfach 3255  
CH-4002 Basel(CH)**

(72) Inventor: **Lesslauer, Werner  
288 Aeussere Baselstrasse  
CH-4125 Riehen(CH)  
Inventor: Lötscher, Hansruedi  
18 Frankenstrasse  
CH-4313 Möhlin(CH)  
Inventor: Stüber, Dietrich  
9 Bandweg  
W-7889 Grenzach-Wyhlen(DE)**

(74) Representative: **Mezger, Wolfgang, Dr. et al  
Grenzacherstrasse 124  
Postfach 3255  
CH-4002 Basel (CH)**

(54) **TNF-Muteins.**

(57) The present invention is directed to a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof having selective binding affinity for the human p55-Tumor-Necrosis-Factor-Receptor characterized in that the amino acid sequence of human Tumor Necrosis Factor is changed at least at position 86 showing a threonine instead of a serine residue, a DNA sequence coding for such a mutein, a vector comprising such a DNA sequence, a host cell transformed by such a vector, a process for the production of such muteins by such host cells, pharmaceutical compositions containing such a mutein and the use of such a mutein for the treatment of illnesses.

**EP 0 563 714 A3**



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

Application Number

EP 93 10 4591

Page 1

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
A	PROTEIN ENGINEERING. vol. 4, no. 4, April 1991, EYNHAM, OXFORD, ENGLAND GB pages 385 - 389 C. R. GOH ET AL 'structural and functional domains in human tumor necrosis factors' the whole document especially the conclusions ---	1	C12N15/28 C12P21/02 C07K13/00 C12N1/21 A61K37/02
D,P, A	EP-A-0 486 908 (F. HOFFMANN-LA ROCHE)  * the whole document * ---	1-12	
A	US-A-4 948 875 (SHOJI TANAKA ET AL)  * the whole document * ---  -/--	1-12	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 5)
			C07K C12N C12P
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims</p> <p>Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search THE HAGUE		Date of completion of the search 08 SEPTEMBER 1993	Examiner LE CORNEC N.D.R.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons @ : member of the same patent family, corresponding document	



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 93 10 4591  
Page 2

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	EMBO JOURNAL. vol. 10, no. 4, April 1991, EYNHAM, OXFORD GB pages 827 - 836 X. VAN OSTADE ET AL 'Localization of the active site of human tumor necrosis factor (hTNF) by mutational analysis' * the whole document *  -----	1	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 5)





Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

SHEET C

EP 93104591.8

**Remark** : Although claim 12 is directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.